Current assays of human committed-stem cells are of limited value in predicting the rate of engraftment or in assessing the integrity of the stem cell pool after allogeneic bone marrow (BM) transplantation (BMT). We have used a limiting dilution assay of mafosfamide-resistant progenitors (pre-colony-forming units [CFU]), which are ancestral to committed progenitors such as CFU-granulocyte-macrophage (GM) to analyze the kinetics of myeloid engraftment after BMT and to assess the size of the stem cell pool at intervals up to 66 months thereafter. In 24 patients transplanted for chronic myeloid leukemia in chronic phase (eight with matched unrelated donors and 16 with sibling donors), the rate of neutrophil engraftment correlated strongly with the number of pre-CFU transfused per kilogram recipient body weight (r = .7, P < .005) but not with CFU-GM per kilogram or nucleated cells per kilogram. In 25 patients studied 6 to 66 months after allogeneic BMT, the mean number LTHOUGH the repopulating capacity of human bone A marrow (BM) cannot be measured directly, some in vitro systems, such as growth of the long-term culture-initiating cell, assay primitive cells believed to be close if not identical to the stem cells responsible for long-term engraftment. However, these assays are generally difficult to perform and quantify, and no studies of the repopulating capacity of primitive hematopoietic progenitors in humans have been published to our knowledge. Similar problems apply to any attempt to analyze the kinetics of recovery of BM stem cell numbers after BM transplantation (BMT). Thus, the recovery of hematopoiesis after BMT is usually monitored by the increase in peripheral blood counts and is sometimes considered complete when these parameters have normalized; colony-forming units-granulocyteimacrophage (CFU-GM) levels in the marrow may take longer to recover than peripheral blood cell counts, but are generally in the normal range by 1 to 2 years after allogeneic or autologous BMT.'-3 However, studies in animals have shown that chemotherapy4 and radiotherapy,' as well as BMT,6-' cause permanent reductions in the more primitive stem cells responsible for repopulation, as measured by the level of CFU-spleen and serial transplantation studies. These observations cast doubt on the value of assessing the marrow CFU-GM level as a true index of marrow integrity in man.
Current assays of human committed-stem cells are of limited value in predicting the rate of engraftment or in assessing the integrity of the stem cell pool after allogeneic bone marrow (BM) transplantation (BMT). We have used a limiting dilution assay of mafosfamide-resistant progenitors (pre-colony-forming units [CFU] ), which are ancestral to committed progenitors such as CFU-granulocyte-macrophage (GM) to analyze the kinetics of myeloid engraftment after BMT and to assess the size of the stem cell pool at intervals up to 66 months thereafter. In 24 patients transplanted for chronic myeloid leukemia in chronic phase (eight with matched unrelated donors and 16 with sibling donors), the rate of neutrophil engraftment correlated strongly with the number of pre-CFU transfused per kilogram recipient body weight (r = .7, P < .005) but not with CFU-GM per kilogram or nucleated cells per kilogram. In 25 patients studied 6 to 66 months after allogeneic BMT, the mean number LTHOUGH the repopulating capacity of human bone A marrow (BM) cannot be measured directly, some in vitro systems, such as growth of the long-term culture-initiating cell, assay primitive cells believed to be close if not identical to the stem cells responsible for long-term engraftment. However, these assays are generally difficult to perform and quantify, and no studies of the repopulating capacity of primitive hematopoietic progenitors in humans have been published to our knowledge. Similar problems apply to any attempt to analyze the kinetics of recovery of BM stem cell numbers after BM transplantation (BMT). Thus, the recovery of hematopoiesis after BMT is usually monitored by the increase in peripheral blood counts and is sometimes considered complete when these parameters have normalized; colony-forming units-granulocyteimacrophage (CFU-GM) levels in the marrow may take longer to recover than peripheral blood cell counts, but are generally in the normal range by 1 to 2 years after allogeneic or autologous BMT.'-3 However, studies in animals have shown that chemotherapy4 and radiotherapy,' as well as BMT,6-' cause permanent reductions in the more primitive stem cells responsible for repopulation, as measured by the level of CFU-spleen and serial transplantation studies. These observations cast doubt on the value of assessing the marrow CFU-GM level as a true index of marrow integrity in man.
Hematopoietic progenitors resistant to the agent, 4-hydroperoxycyclophosphamide (4HC), or its congener, mafosfamide, are believed to be ancestral to CFU-GM and other committed progenitors. A previously described assay of 4HC-resistant progenitors, the "delta" assay, measures the generation of CFU-GM in liquid culture after 7 days. Since these progenitors appear able to generate CFU-GM in culture, they have been termed pre-CFU. However, measurement of CFU-GM generation in bulk liquid culture is dependent not only on the number of pre-CFU present in the sample but also on their proliferation in culture, which is in turn dependent on the growth factors present in the delta assay? 4HC-resistant progenitors are believed to include cells capable of repopulating marrow after BMT,'' so a quanof pre-CFU in the marrow was 3.1/106 mononuclear cells (MNC) (median. 3.47; range, 0.4 to 23.3). compared with 24.7/105 MNC (median. 27.3; range, 4.2 to 180) in 25 normal subjects. CFU-GM were also reduced in these patients, but with considerable overlap into the normal range (mean f SD: 54 f 45.6 per lo5 MNC; normal, 129 f 61.6). Low pre-CFU but not low CFU-GM levels were associated with reduced peripheral blood white blood cell counts in post-BMT patients. Pre-CFU and CFU-GM levels were not related to the interval posttransplant and remained low for up to 66 months. We conclude that the pre-CFU assay measures a population of stemlprogenitor cells that are important in the kinetics of engraftment after allogeneic BMT. Our data suggest that pre-CFU levels may remain low for some years after BMT in humans.
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titative assay of pre-CFU may prove to be of value in assessing the kinetics of engraftment after BMT and may provide insights into the effects of BMT on more primitive stem cell populations than CFU-GM. Herein we describe a new limiting dilution assay (LDA) for mafosfamide-resistant pre-CFU that is simple to perform linear, and reproducible, and we demonstrate that pre-CFU can be quantified directly using Poisson statistics. We have used this assay to quantify pre-CFU before and after BMT and have found that large numbers of allogeneic pre-CFU transfused may be predictive of a short time to neutrophil engraftment, and that pre-CFU levels in the patient's BM may remain markedly reduced for up to 66 months after BMT.
MATERIALS AND METHODS
BM samples were obtained from 25 consecutive normal individuals donating marrow for allogeneic BMT for chronic myeloid leukemia (CML). BM cells were also obtained from 25 CML patients 6 to 66 months after allogeneic BMT as part of routine clinical follow-up evaluation. Informed consent for the donations was obtained in each case. In 24 of 25 normal BM donations, the rate of engraftment was measured in the graft recipient. Representative mafosfamide dose-response study on a normal BM sample. Doseresponse studies were performed on 3 normal BM samples for each batch of mafosfamide at concentrations of 100 t o 750 pmol/L. CFU-GM survival was measured using a methylcellulose assay system with 5637 CM as the source of growth factor, and LDAs were performed at each dose. An optimal dose was chosen as the dose that killed >95% of CFU-GM and at which the frequency of clones in the LDA was in a plateau (between the dashed lines: in this case, 250 t o 350 pmol/L) and therefore represented mafosfamideresistent pre-CFU. At doses of mafosfamide less than this, the LDA frequency consists of residual CFU-GM plus pre-CFU, leading t o parallel curves; at greater doses, mafosfamide is also toxic t o pre-CFU.
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were isolated by centrifugation over Lymphoprep (density = 1.077: Nycomed Pharma, Oslo, Norway).
Recombinant human interleukin-lp (IL-IB), IL-3, and IL-6 were purchased from Genzyme Inc (Cambridge, MA). Recombinant human stem cell factor (SCF) was a gift from Amgen Ltd (Cambridge, UK). Mafosfamide was a gift from Asta Medica (Frankfurt, Germany).
BM-MNC were diluted to 5 X IO' / mL in alpha-modified minimum essential medium ([MEM] GIBCO-BRL, Scotland) containing 10% fetal calf serum ([FCS] Flow Laboratories, Scotland) and then incubated with 200 to 300 pmol/L mafosfamide (precise concentration determined by preliminary batch testing) for 30 minutes at 37°C. The cells were washed twice in cold Hanks' balanced salt solution and then resuspended in the initial volume of MEM. The cells were then plated in 96-well plates at reducing cell concentrations (usually 9,000, 3,000, I.OO0, and 333 cells per well), 48 wells per dilution, in MEM containing 20% FCS, 20 ng/mL SCF, 100 U/mL IL-ID, 100 U/mL IL-6, and 50 nglmL IL-3. Plated cell concentrations were based on the initial cell count before mafosfamide treatment. Clones were scored at 18 to 21 days under an inverted microscope as aggregates of more than 20 viable small cells. Morphologically identifiable monocytes and fibroblasts were excluded.
CFU-GM assays were performed in triplicate in 1% methylcellulose containing 20% FCS, 10% medium conditioned by the cell line 5637, L-glutamine, and penicillin-streptomycin. Aggregates containing 40 or more cells were scored as colonies after incubation at 37°C in 5% C 0 2 for 12 to 14 days.
The frequency of clonogenic cells at each dilution was determined using the Poisson equation,
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where m is the frequency of clonogenic cells, f is the number of cells seeded into each well, In is the natural log. and Po is the proportion of empty wells. The frequency of clonogenic cells in the sample can be determined from the LDA using minimization of x' as described by Taswell." x2 analysis was used to confirm linearity of the data (with df = 1 less than the number of data points used), and results indicated that colony growth was dependent on the presence of a single progenitor.
For personal use only. on September 14, 2017. by guest www.bloodjournal.org From There is substantial variability in the number of secondary CFU-GM produced by each pre-CFU. The mean CFU-GM/pre-CFU level is calculated assuming that 1 of the positive wells contained 2 pre-CFU.
The gamma distribution was calculated using the GAMMADIST function in Microsoft Excel version 5 
RESULTS
Characterization of the assay. The concentration of mafosfamide used was determined in preliminary experiments as described in Fig 1. All experiments included CFU-GM assays on samples after mafosfamide treatment. The few experiments in which 95% killing of CFU-GM was not achieved or in which the number of residual CFU-GM was greater than 20% of the number of progenitors detected in the LDA were excluded from subsequent analysis (four of 83 assays) on the basis that residual CFU-GM were contributing to the number of positive wells scored. In 70 of 79 assays, little or no growth of CFU-GM (0 to 5/105 MNC) was observed in these postmafosfamide CFU-GM assays.
Positive wells were easily distinguished from negative wells after 18 to 21 days of incubation (Fig 2) . Replating of positive wells from low-density cultures (where the proportion of empty wells was >0.8 and the probability for each well to contain the progeny of a single cell was >85%) showed variable secondary CFU-GM formation ( Table 1) . The cumulative frequency of secondary CFU-GM formation approximates to a gamma distribution (Fig 3) . Wells scored as negative did not contain secondary CFU-GM (data not shown).
Addition of further growth factors (GM-CSF and/or G-CSF) did not alter the frequency of pre-CFU detected, but did increase the number of cells and CFU-GM generated by each clone ( Table 2) .
Linearity of the assay was confirmed by x2 analysis," which produced a probability for the data to conform to a linear distribution (defined as a x2 value corresponding to P > .05) in 74 of 79 LDA assays. This indicates that the presence of a positive well is probably dependent on the growth of a single cell. Reproducibility of the assay was assessed in two experiments by splitting a sample of BM-MNC into five separate aliquots, treating each separately with mafosfamide, and performing LDAs on aliquots. These studies showed a coefficient of variation of 14% and 18% (data not shown). In a separate experiment, replicate assays performed on a single sample after mafosfamide treatment showed a coefficient of variation of 2.8%, suggesting that a major source of variability in the assay lies in the washing steps after mafosfamide treatment.
Correlation with engraftment. In 24 BMT recipients (8 matched unrelated donor [MUD] BMT and 16 sibling BMT), it was possible to analyze the relationship between three parameters (total nucleated cells, total CFU-GM, and total pre-CFU) in the donor BM and the time to adequate engraftment in the recipient as measured by the days required to reach 500 X 10% neutrophils. There was a strong correlation between the time taken to achieve neutrophil engraftment and total pre-CFU numbers administered per kilogram recipient body weight ( r = -.702, P < ;005; Fig 4) .
When analyzed separately, this correlation was found to exist for sibling BMT ( r = 644, P < .01) but not for MUD BMT ( r = .04, P > .9), perhaps reflecting the many complicating variables affecting the rate of engraftment in the latter group. No such correlation was seen with either total nucleated cell counts or total CFU-GM ( r = -.262 and r = .369, respectively, both P > .I).
Quantitation of pre-CFU and CFU-GM in normal and post-BMT BM. The frequency of pre-CFU and CFU-GM in 25 normal BM samples and in 25 post-BMT samples is shown in Table 3 . Pre-CFU frequencies were found to be log-normally distributed, whereas CFU-GM were normally distributed. Pre-CFU levels were significantly reduced after Table 1 ) compared with a theoretical gamma distribution generated using the same mean, standard error, and variance as the observed population.
For personal use only. on September 14, 2017. by guest www.bloodjournal.org From Pre-CFU LDAs were performed in the presence of different growth factor combinations consisting of the basic 4 factors (IL-1, IL-3, IL-6, and SCF) with the addition of GM-CSF, G-CSF, and EPO as shown. Cells from high-density cultures (9,000 cells/well) were pooled after 18 days (experiment 1) or 14 days (experiment 2), and cell counts and CFU-GM assays were performed. Mean values for cells/pre-CFU and CFU-GM/ pre-CFU were calculated using the level of pre-CFU/105 MNC determined from the LDA.
* Significantly greater than with SCF/IL-l/IL-3/IL-6 alone ( P < .05, Student's t-test).
BMT (Fig 5A) . CFU-GM were also reduced in post-BMT samples (Fig 5B) , but showed considerably greater overlap with the normal range than pre-CFU. Nine of 25 post-BMT patients had reduced peripheral blood leukocyte counts (range, 1.7 to 3.0 X lo9&; normal, > 3.9) at the time the BM sample was taken. There was a poor correlation between CFU-GM and pre-CFU in each of the two study groups (Y = .39 in normal BM, r = .35 in post-BMT samples, both P < .I). However, examination of the data suggests that there may be a threshold effect, since post-BMT samples with pre-CFU frequencies less than 2 3 1 O5 MNC invariably had low levels of CFU-GM. Seven of eight patients with pre-CFU levels less than this value also had low peripheral blood leukocyte counts at the time of the assay, whereas only two of the remaining 17 patients had a reduced leukocyte count ( P < .001, Fisher's exact test; P < .005, Mann-Whitney U test). Reduced CFU-GM levels were not associated with low leukocyte counts ( P > 0.1, Fisher's exact test and MannWhitney U test using a cutoff of 30 CFU-GM/l@ MNC; P > . I , rank-sum test). In post-BMT samples, there was no correlation between CFU-GM or pre-CFU levels and time since BMT ( r = . l 1 and r = -.08, respectively, both P > .1). Re-CFU remained significantly reduced for a number of years after BMT in 17 of 25 patients (Fig 6) . CFU-GM were normal in 12 of 25 patients and only mildly reduced (25 to 40/1@ MNC) in another nine patients.
DISCUSSION
Quantitation of human hematopoietic progenitors that are more primitive than CFU-GM is technically demanding with many of the assay systems currently in use. We have therefore set out to develop an assay that is relatively simple to perform and quantify by using a LDA in the pre-CFU assay reported by Moore.' The use of a LDA has the advantage that the end point (positive or negative wells) is independent of the rate of proliferation of the progenitors and therefore less dependent on growth conditions. The theoretical disadvantage is that the production of CFU-GM by each clone is not measured, and it is therefore not certain that all of the wells scored as positive do in fact contain the progeny of pre-CFU. However, we have found that secondary CFU-GM, presumably derived from pre-CFU, could be detected in more than 85% of wells scored as positive. The number of secondary CFU-GM generated by individual clones was highly variable. Although this variability may reflect the heterogeneity of the population being studied, it is also possible that it is the result of the process of commitment being stochastic in nature, since the cumulative frequency of committed progenitors approximates a gamma distributi~n.'~,'~ We have also confirmed that the number of secondary CFU- *P < ,00001 (Mann-Whitney rank-sum).
t P < ,0001 (Student's t-test).
For GM generated by each pre-CFU (but not the number of pre-CFU) is dependent on the growth factor conditions used, validating the use of a LDA for quantitation of these cells.
Agents such as 4HC/mafosfamide and 5-fluorouracil kill committed progenitors but leave more primitive cells (including long-term culture-initiating cells) relatively intact.10.14.15
These more primitive cells include those responsible for BM repopulation after BM or peripheral blood stem cell transplantation.16-'* We hypothesized that quantitation of mafosfamide-resistant stem cells might provide important insights into the effects of transplantation on hematopoietic stem cells. We have therefore used the pre-CFU LDA to address two questions related to the kinetics of BM engraftment in allogeneic BMT. First, does the pre-CFU dose given to the recipient correlate with the rate of engraftment, and second, do pre-CFU recover to normal levels in longterm stable engraftment?
To address the first question, we have analyzed the rate of engraftment in 24 patients undergoing HLA-matched sibling or MUD transplantation for CML. There was a correlation between the total number of pre-CFU per kilogram but not CFU-GM or nucleated cells per kilogram infused and the rate of neutrophil engraftment in sibling allogeneic BMT. A relationship between CFU-GM levels and the kinetics of engraftment in allogeneic BMT has been observed previously by some group^'^-'^ but not and a similar disparity of results showing a correlation23 or no correlation24-26 has been seen in studies in autologous BMT. Two groups have found the more primitive CFU-Mix to be a better predictor of rec0very,2~~~~ consistent with the concept that measurements of more primitive populations of progenitors are more indicative of repopulating potential.
To address the second question, we compared the frequency of pre-CFU and CFU-GM in patients from 6 to 66 months after allogeneic BMT versus that in normal BM. Some groups have reported that CFU-GM numbers are lowz7 or even absentz8 after BMT, and others have reported normalization of the numbers by 60 days" to 2 years.'.' The disparity between these findings may in part reflect differences in the patient populations studied and in the myeloid colony assays used, since normal ranges varied greatly. Our study yielded results intermediate between these two extremes: CFU-GM normalized in some patients but remained low in others for up to 5 years after BMT. Although some studies found a relationship between CFU-GM levels and time after BMT, at least in the first 6 to 12 months, no such relationship was seen in our data, but longitudinal and cross-sectional studies will be needed to confirm this.
Animal studies have suggested that there may be a more severe reduction in primitive repopulating cell numbers after BMT than is suggested by studies of committed progenitors. A number of groups have demonstrated reduced repopulating capacity in mice after BMT6,7*'9-31 or after exposure to irradia- For personal use only. on September 14, 2017. by guest www.bloodjournal.org From tion or cytotoxic drugs,?.' but there are no previous studies of the effects of BMT on more primitive stem cell populations in man. We have demonstrated a deficit of pre-CFU after allogeneic BMT that is considerably more profound than that estimated from CFU-GM assays. The mean number of pre-CFU/105 MNC detected after BMT is almost one order of magnitude less than found in normal BM donors, and the overlap between normal and postBMT levels was substantially less than seen with CFU-GM.
Most of the patients with low numbers of pre-CFU had normal peripheral blood cell counts at the time these assays were performed. It therefore appears that the deficit in primitive stem cells can be partially masked at the level of committed progenitors and completely masked at the level of mature cells, presumably as a result of increased proliferation of intermediate progenitors. The lack of correlation between CFU-GM and pre-CFU in normal BM in this study is therefore to be expected, since committed progenitors can be viewed as reflecting both the number of primitive progenitors and the demand for end cells. A decreased number of pre-CFU may be able to maintain a normal number of CFU-GM and mature cells as a result of feedback regulation. Our data have shown a correlation between very low pre-CFU numbers (<2.5/105 MNC) and low CFU-GM and peripheral leukocyte counts, suggesting that there is a level of pre-CFU below which neither CFU-GM levels nor peripheral blood white blood cell counts can be adequately maintained.
It was not the aim of this study to compare the pre-CFU LDA with other assays of primitive progenitors, and it is not possible on the basis of these data to draw any conclusions as to the degree of "primitiveness" of pre-CFU, other than that they are ancestral to CFU-GM. However, the observation that mafosfamide-resistant progenitors include cells responsible for repopulation and long-term reconstitution after BMT,"'.'h-'X together with our observation that pre-CFU quantified by LDA correlate with the rate of engraftment in allogeneic BMT, suggests that this assay may be measuring a population of cells of clinical relevance. The simplicity, reproducibility, and easy interpretation of this assay may make it useful in the assessment of repopulating potential in some clinical settings.
